Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase NA 1Phase 4 1

Status

Unknown 34Completed 25Recruiting 13Terminated 7Not yet recruiting 6Active not recruiting 3Withdrawn 2

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Stomach Neoplasms 3Pancreatic Neoplasms 1HER2-positive Gastric Cancer 1Efficacy and Safety 1

Interventions

Cisplatin 122Carboplatin 120Drug Therapy 104Bevacizumab 101Capecitabine 96Oxaliplatin 95Radiotherapy 92Gemcitabine 88Paclitaxel 87tislelizumab 84Cyclophosphamide 83Specimen Handling 80pembrolizumab 76toripalimab 66Magnetic Resonance Spectroscopy 63Fluorouracil 61sintilimab 58Injections 57anlotinib 51Docetaxel 51Surgical Procedures, Operative 48130-nm albumin-bound paclitaxel 48fludarabine 45Pemetrexed 43Standard of Care 42Biopsy 42venetoclax 41Irinotecan 41lenvatinib 40Leucovorin 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Not yet recruiting × Interventional × Tegafur × Clear all
NCT07262567 2025-12-03

Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer

Genfleet Therapeutics (Shanghai) Inc.

Phase 3 Not yet recruiting
320 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06603974 2024-09-19

EASOBFGE

Xijing Hospital

Phase NA Not yet recruiting
48 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05498766 2024-06-24

Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 4 Not yet recruiting
702 enrolled
Gastrointestinal

Stomach Neoplasms

NCT06439550 2024-06-03

Adjuvant Treatment With Serplulimab,Trastuzumab and SOX in the HER-2 Positive GC/GEJC

The First Affiliated Hospital of Zhengzhou University

Phase 2 Not yet recruiting
42 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT06383078 2024-04-25

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
120 enrolled

Efficacy and Safety

NCT05914610 2023-08-25

Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer

Fujian Medical University

Phase 3 Not yet recruiting
100 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡